Quantbot Technologies LP Has $1.46 Million Stock Position in Omnicell, Inc. $OMCL

Key Points

• Quantbot Technologies LP increased its position in Omnicell, Inc. by 64.5% during the first quarter, owning 41,819 shares valued at $1.46 million.
• Several institutions have made new acquisitions in Omnicell's stock, with institutional investors owning approximately 97.70% of the company's shares.
• Omnicell's shares have experienced a price target adjustment, with Wells Fargo raising it to $40.00, while other analysts have set targets between $34.00 and $62.00, leading to a consensus rating of "Moderate Buy."

Quantbot Technologies LP grew its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 64.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,819 shares of the company's stock after buying an additional 16,397 shares during the quarter. Quantbot Technologies LP owned approximately 0.09% of Omnicell worth $1,462,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in shares of Omnicell in the fourth quarter worth about $37,000. Point72 Hong Kong Ltd acquired a new position in shares of Omnicell in the fourth quarter worth about $101,000. Corton Capital Inc. acquired a new position in shares of Omnicell in the fourth quarter worth about $208,000. Caption Management LLC acquired a new position in shares of Omnicell in the fourth quarter worth about $223,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Omnicell in the fourth quarter worth about $286,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on OMCL. Wells Fargo & Company raised their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Piper Sandler reduced their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Benchmark reduced their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Bank of America increased their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Omnicell currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Price Performance

Shares of OMCL opened at $33.62 on Friday. The firm has a market cap of $1.54 billion, a PE ratio of 67.24, a PEG ratio of 9.31 and a beta of 0.78. The firm's 50 day moving average price is $29.62 and its 200 day moving average price is $31.92. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.